SCHEMBL2465221

SCHEMBL2465221

Cc1cc(C2(c3cccc(Br)c3)N=C(N)c3c(F)cccc32)cc(C(F)F)n1

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.58
KCNH2 Q12809 17/20 0.58
BACE2 Q9Y5Z0 6/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465101 0.91 BACE1 (0.69) BACE1KCNH2BACE2
SCHEMBL7698585 0.85 BACE1 (0.71) BACE1KCNH2BACE2
SCHEMBL1356685 0.85 BACE1 (0.71) BACE1KCNH2BACE2
SCHEMBL2466479 0.84 BACE1 (0.84) BACE1KCNH2BACE2
SCHEMBL2462926 0.83 BACE1 (0.57) BACE1KCNH2BACE2
SCHEMBL3360116 0.83 BACE1 (0.39) BACE1KCNH2BACE2
SCHEMBL2468040 0.81 BACE1 (0.53) BACE1KCNH2BACE2
SCHEMBL2465003 0.79 BACE1 (0.68) BACE1KCNH2BACE2
SCHEMBL2463250 0.77 BACE1 (0.69) BACE1KCNH2BACE2
SCHEMBL12136046 0.76 BACE1 (0.71) BACE1KCNH2BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319426-A1 Substituted Isoindoles ASTRAZENECA AB (SE) 2011-12-29 US disclosed
US-20110319426-A1 Substituted Isoindoles ASTRAZENECA AB (SE) 2011-12-29 US disclosed
US-20110319426-A1 Substituted Isoindoles ASTRAZENECA AB (SE) 2011-12-29 US disclosed
CN-102282140-A New compounds 578 2011-12-14 CN disclosed
US-8030500-B2 Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies ASTRAZENECA AB (SE) 2011-10-04 US disclosed
US-8030500-B2 Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies ASTRAZENECA AB (SE) 2011-10-04 US disclosed
US-8030500-B2 Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies ASTRAZENECA AB (SE) 2011-10-04 US disclosed
EP-2367814-A1 NEW COMPOUNDS 578 AstraZeneca AB (SE) 2011-09-28 EP disclosed
US-20100125082-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 US disclosed
US-20100125082-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 US disclosed
US-20100125082-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 US disclosed
WO-2010056196-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 WO disclosed
WO-2010056196-A1 NEW COMPOUNDS 578 ASTRAZENECA AB (SE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125082-A1 NEW COMPOUNDS 578 PSEN1, PSEN2, BACE1 BACE1 3/4885KCNH2 4686/4885BACE2 10/4885
US-20110319426-A1 Substituted Isoindoles PSEN2, PSEN1, SNCA BACE1 6/4885KCNH2 4588/4885BACE2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.